Cardiff Oncology, Inc. Q1 FY2024 earnings call

1. Mark Erlander discussed the clinical development plan for onvansertib focused on first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), with Q1 2024 adding 3 data sets supporting this strategy, including ONSEMBLE data, AACR posters, and Clinical Cancer Research publication. 2. At AACR, presented data on lead program in RAS-mutated mCRC, preclinical data in RAS wild-type mCRC, small cell lung cancer, and ovarian cancer. 3. CRDF-004 trial is ongoing Phase II evaluating first-line RAS-mutated mCRC, with 24 activated clinical trial sites, and initial data readout timing pushed to Q3-Q4 2024 due to enrollment pace. 4. Financial position: cash and short-term investments as of March 31, 2024 totaled $67.2 million, with cash runway into Q3 2025.

No specific product segment financial performance data provided as the focus is on clinical development and trial updates.

1. Initial data readout from CRDF-004 trial now expected in Q3-Q4 2024 instead of earlier Q2-Q3 due to enrollment pace. 2. Cash resources provide runway into Q3 2025, well beyond the updated timing for CRDF-004 initial readout.

1. Forward-looking statements involve significant risks and uncertainties, including factors described in the Risk Factors section of the Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2023.

Q: Maybe just to start off on the tweak to guidance on when the interim data might become available. Can you just maybe clarify how much of the small pushout was really kind of the enrollment pace once sites are open versus maybe just some delays getting the sites up and running as quickly as you'd hoped?

A: Mark Erlander explained that the pushout was due to enrollment pace, with high enthusiasm from principal investigators but the need to accurately project data share based on enrollment.

Q: With the slight push in the initial readout from 004, I'm wondering if there's a possibility of maybe seeing another cut of the ONSEMBLE cohort before them just -- before then, just getting longer follow-up and a better sense of the durability of responses and how that's shaking out between the arms of the trial, the bev-naive, bev-experienced.

A: Mark Erlander stated that as of now, they don't have plans to have a continued follow-up of the ONSEMBLE data.

Q: A couple of quick ones from us, if you don't mind. So in terms of clinical sites, I believe, Mark, you said 24 sites right now. I believe it was 20 before. And is your end-goal being 30 total by the end of the enrollment completion?

A: Mark Erlander said their goal is to activate 35 sites, with the number being dynamic as they go through the trial and continue to activate sites.

Q: Great. And maybe, like, my last question has to do with catalyst events. So Jamie, you talked about Q3 2025 being the cash runway. Perhaps, can you give us maybe a big-picture view? Obviously, 004 study happening in the second half of this year. Any other potential data readouts that you can expect in the first 3 quarters of 2025 that could allow us to better appreciate the clinical activity of onvansertib?

A: Mark Erlander said they are not prepared to set dates for investigator-initiated trials' data readouts at this point but are laser-focused on the 004 trial.